AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s stock price was up 3.5% during trading on Thursday . The stock traded as high as $4.33 and last traded at $4.17. Approximately 79,551 shares changed hands during mid-day trading, an increase of 407% from the average daily volume of 15,685 shares. The stock had previously closed at $4.03.
AlloVir Trading Down 1.2%
The business’s 50 day moving average price is $4.22 and its two-hundred day moving average price is $5.98. The stock has a market cap of $20.78 million, a P/E ratio of -0.20 and a beta of 0.63.
About AlloVir
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Further Reading
- Five stocks we like better than AlloVir
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
- Flash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch
- MarketBeat Week in Review – 08/17 – 08/21
- Blueprint for a Boom: SEC Clears the Crypto Runway
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
